Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer

Project Oncology®

Host: Javier Cortes, MD, PhD
Guest: Komal Jhaveri, MD, FACP
The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly improved outcomes for patients in this setting. However, selecting the appropriate ADC and determining the optimal sequencing of these therapies may be challenging. In this activity, expert faculty in the field of breast cancer review the clinical burden related to endocrine-refractory disease, the role of ADCs in this setting, and best practices for the sequencing of these agents.